Is autologous stem cell transplantation still the backbone of multiple myeloma treatment?
How can MRD and disease be assessed in routine practice?
Do we need to stratify follicular lymphoma (FL) patients for treatment?
What do current multiple myeloma clinical trials have in common?
Are we ready to use minimal residual disease (MRD) to direct multiple myeloma therapy?